Geron Corporation (GERN) key performance indicators and operating metrics (23 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| RYTELO ordering accounts | 1.58K | FY2026-Q2 |
| RYTELO demand growth | 5.00 percent | FY2026-Q2 |
| Net product revenue | 57.47M | FY2026-Q2 |
| RYTELO first- and second-line new patient starts | 36.00 percent | FY2025-Q3 |
| Prescribing account growth | 13.00 percent | FY2025-Q4 |
| Estimated U.S. lower-risk myelodysplastic syndrome patients | 8K | FY2026-Q2 |
| Gross-to-net deductions | 20.70 percent | FY2026-Q2 |
| Royalty revenue | 7K | FY2026-Q2 |
| U.S. covered lives under favorable RYTELO coverage policies | 90.00 percent | FY2025-Q2 |
| IMpactMF enrollment | 95.00 percent | FY2025-Q2 |
| New RYTELO sites of care | 400.00 | FY2025-Q2 |
| RYTELO-utilizing sites of care | 1K | FY2025-Q2 |
| RYTELO ordering centers | 590.00 | FY2024-Q4 |
| Ordering centers share of key targeted accounts | 70.00 percent | FY2024-Q4 |
Back to GERN overview · GERN earnings · GERN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.